Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised cross-over study of Gammanorm 165 mg/mL with two subcutaneous delivery devices in adults with primary immunodeficiency
2014-003746-27Phase 3Completed
- Sponsor
- Octapharma
- Start
- Dec 2014
- Countries
- 1
01
Overview
Phase 3, randomised trial of ALYGLO in Immunogenetic disorder (2 arms), sponsored by Octapharma. Primary endpoint: Patient satisfaction score. Started Dec 2014; status: completed.
02
Drugs
ALYGLO
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2014-003746-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003746-27.